Roche (company)
Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study
Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche
Roche’s Chugai Enters $780M Deal with Swiss ADC Specialist Araris Biotech
Roche, Chugai, Araris Biotech, ADC, Antibody-Drug Conjugate, Biotech Deal
Roche’s Prasinezumab Fails Primary Endpoint in Phase 2b Parkinson’s Trial, Shows Promising Trends
Roche, Prothena, Parkinson’s disease, prasinezumab, alpha-synuclein, phase 2b trial, PADOVA study
Roche’s Parkinson’s Drug Fails Second Mid-Stage Trial, Yet Shows Promising Trends
Roche, Parkinson’s disease, prasinezumab, clinical trial failure, promising trends, further exploration
Roche Discontinues Second Hemophilia A Gene Therapy Candidate Under Spark Amid Shift in Hematologic Portfolio
Roche, Spark Therapeutics, Hemophilia A, Gene Therapy, RG6358, SPK-8016, Hemlibra, SPK-8011
From Partnership to Acquisition: The $1.5 Billion Journey of Roche and Poseida Therapeutics
Roche Holdings/ Inc., Poseida Therapeutics/ Inc., Allogeneic cell therapy, CAR-T programs, Genetic medicines, Biotech acquisition, Pharmaceutical industry
Roche and COUR Pharmaceuticals Collaborate on Autoimmune Disease Treatment in Deal Worth Over $900 Million
Roche, COUR Pharmaceuticals, autoimmune disease, Genentech, antigen-specific immune tolerance platform, biotech collaboration
Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq
Roche Acquires Poseida Therapeutics for Up to $1.5 Billion, Expanding Off-the-Shelf CAR-T Capabilities
Roche, Poseida Therapeutics, CAR-T therapy, off-the-shelf cell therapies, allogeneic cell therapy, biotech acquisition
Roche Acquires CAR-T Partner Poseida Therapeutics for $1 Billion Upfront
Roche, Poseida Therapeutics, CAR-T, cell therapy, acquisition, biotechnology, pharmaceuticals